Physician profile
Steve Tu
NPI 1922108901
$2,259.48
in general payments reported to CMS, 2019-2025
14 companies · $94.56 in 2025
The $94.56 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $101 · 2021: $286 · 2022: $301 · 2023: $339 · 2024: $1,009 · 2025: $94.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743 · Long Term Medical Supply Or Device Loan: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.40 |
| Long Term Medical Supply Or Device Loan | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $730.58 | 2021-2024 | Dextenza |
| Abbvie INC. | $382.71 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $181.57 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $171.26 | 2022-2025 | Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $134.45 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $133.29 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $128.80 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $108.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $103.27 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $71.12 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $43.89 | 2022-2023 | Acuvue |
| Amgen INC. | $28.10 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $21.14 | 2019 | |
| Horizon Therapeutics Plc | $20.81 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.